News & Updates

Show Multimedia Only

Tirzepatide induces weight loss in overweight/obese patients with T2D

20 Jul 2023 by

Treatment with once-weekly tirzepatide, a GIP* and GLP-1** receptor agonist, led to a substantial weight reduction among overweight or obese adults with type 2 diabetes (T2D), according to the phase III SURMOUNT-2 trial presented at ADA 2023.

Tirzepatide induces weight loss in overweight/obese patients with T2D

20 Jul 2023

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Treatment with tirzepatide is associated with better lipid profile and waist circumference outcomes compared with placebo and other glucose-lowering drugs, according to a study.

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023 by

The THR-β selective agonist resmetirom helps resolve nonalcoholic steatohepatitis (NASH) and reduce fibrosis, with the drug being safe and well-tolerated, according to data from the large phase III pivotal MAESTRO-NASH trial presented at EASL 2023.

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Baseline glycated haemoglobin (HbA1c) is the most robust risk factor for metformin failure, reveals a study, noting that routinely available clinical data may be used to identify high-risk patients who may benefit from closer monitoring and earlier treatment intensification.

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Which factors promote inappropriate prescribing among older patients in primary care?

19 Jul 2023 by

Several factors contribute to potentially inappropriate prescribing (PIP) among older persons in primary care settings, and these elements can be classified into patient, physician, and system, according to a Singapore study. These factors can help in designing complex interventions for PIP and in developing risk prediction tools to identify groups who may need further PIP-related interventions.

Which factors promote inappropriate prescribing among older patients in primary care?

19 Jul 2023

S-ITM lesions predict relapse in cutaneous SCC

19 Jul 2023

In patients with cutaneous squamous cell carcinoma (cSCC) presenting with satellitosis or in-transit metastasis (S-ITM), the size and the number of S-ITM lesions are associated with a higher risk of relapse, while the number of S-ITM confers an increased risk of specific death, reveals a study.

S-ITM lesions predict relapse in cutaneous SCC

19 Jul 2023

Anti-obesity therapies go beyond weight loss

19 Jul 2023 by

Weight loss strategies do not only provide therapeutic alternatives for obesity but may also hold promise in the management of type 2 diabetes (T2D) and NAFLD*.

Anti-obesity therapies go beyond weight loss

19 Jul 2023

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

19 Jul 2023

Brolucizumab helps improve visual and anatomic outcomes in diabetic macular edema (DME), with long-term efficacy and durability and no new safety signals, as shown in the 100-week data from the phase III KESTREL and KITE studies.

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

19 Jul 2023

Azithromycin use poses acute heart failure, mortality risks for some COVID-19 patients

18 Jul 2023

Exposure to azithromycin may put patients with COVID‐19 and history of cardiovascular disease (CVD) at higher risks of acute heart failure and death, as reported in a study.

Azithromycin use poses acute heart failure, mortality risks for some COVID-19 patients

18 Jul 2023

Novel lotion formulation helps reduce palm sweating

18 Jul 2023

A new lotion formulation of 20% oxybutynin hydrochloride (20% OL) demonstrates efficacy in reducing palmar sweat volume among patients with primary palmar hyperhidrosis (PPHH) when compared with placebo, results of a phase III study have shown.

Novel lotion formulation helps reduce palm sweating

18 Jul 2023

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Tirzepatide induces weight loss in overweight/obese patients with T2D

Tirzepatide induces weight loss in overweight/obese patients with T2D

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Baseline HbA1c strongly predicts metformin failure

Baseline HbA1c strongly predicts metformin failure

Which factors promote inappropriate prescribing among older patients in primary care?

Which factors promote inappropriate prescribing among older patients in primary care?

S-ITM lesions predict relapse in cutaneous SCC

S-ITM lesions predict relapse in cutaneous SCC

Anti-obesity therapies go beyond weight loss

Anti-obesity therapies go beyond weight loss

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

Long-term data confirm efficacy, durability of brolucizumab in diabetic macular edema

Azithromycin use poses acute heart failure, mortality risks for some COVID-19 patients

Azithromycin use poses acute heart failure, mortality risks for some COVID-19 patients

Novel lotion formulation helps reduce palm sweating

Novel lotion formulation helps reduce palm sweating